Literature DB >> 24547942

Innate immunity drives xenobiotic-induced murine autoimmune cholangitis.

C-H Chang1, Y-C Chen, Y-H Yu, M-H Tao, P S C Leung, A A Ansari, M E Gershwin, Y-H Chuang.   

Abstract

Although primary biliary cirrhosis (PBC) is considered a model autoimmune disease, it has not responded therapeutically to traditional immunosuppressive agents. In addition, PBC may recur following liver transplantation, despite the absence of major histocompatibility complex (MHC) matching, in sharp contrast to the well-known paradigm of MHC restriction. We have suggested previously that invariant natural killer T (iNK T) cells are critical to the initiation of PBC. In this study we have taken advantage of our ability to induce autoimmune cholangitis with 2-octynoic acid, a common component of cosmetics, conjugated to bovine serum albumin (2-OA-BSA), and studied the natural history of pathology in mice genetically deleted for CD4 or CD8 following immunization with 2-OA-BSA in the presence or absence of α-galactosylceramide (α-GalCer). In particular, we address whether autoimmune cholangitis can be induced in the absence of traditional CD4 and CD8 responses. We report herein that CD4 and CD8 knock-out mice immunized with 2-OA-BSA/PBS or 2-OA-BSA/α-GalCer develop anti-mitochondrial antibodies (AMAs), portal infiltrates and fibrosis. Indeed, our data suggest that the innate immunity is critical for immunopathology and that the pathology is exacerbated in the presence of α-GalCer. In conclusion, these data provide not only an explanation for the recurrence of PBC following liver transplantation in the absence of MHC compatibility, but also suggest that effective therapies for PBC must include blocking of both innate and adaptive pathways.
© 2014 British Society for Immunology.

Entities:  

Keywords:  CD4 knock-out mice; CD8 knock-out mice; primary biliary cirrhosis; xenobiotics

Mesh:

Substances:

Year:  2014        PMID: 24547942      PMCID: PMC4226588          DOI: 10.1111/cei.12298

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  48 in total

1.  Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis.

Authors:  S Shimoda; J Van de Water; A Ansari; M Nakamura; H Ishibashi; R L Coppel; J Lake; E B Keeffe; T E Roche; M E Gershwin
Journal:  J Clin Invest       Date:  1998-11-15       Impact factor: 14.808

2.  IL-2 receptor alpha(-/-) mice and the development of primary biliary cirrhosis.

Authors:  Kanji Wakabayashi; Zhe-Xiong Lian; Yuki Moritoki; Ruth Y Lan; Koichi Tsuneyama; Ya-Hui Chuang; Guo-Xiang Yang; William Ridgway; Yoshiyuki Ueno; Aftab A Ansari; Ross L Coppel; Ian R Mackay; M Eric Gershwin
Journal:  Hepatology       Date:  2006-11       Impact factor: 17.425

3.  Increased CD1d expression on small bile duct epithelium and epithelioid granuloma in livers in primary biliary cirrhosis.

Authors:  K Tsuneyama; M Yasoshima; K Harada; K Hiramatsu; M E Gershwin; Y Nakanuma
Journal:  Hepatology       Date:  1998-09       Impact factor: 17.425

Review 4.  New insights to the immunopathology and autoimmune responses in primary biliary cirrhosis.

Authors:  Xiao-Song He; Aftab A Ansari; William M Ridgway; Ross L Coppel; M Eric Gershwin
Journal:  Cell Immunol       Date:  2006-01       Impact factor: 4.868

5.  In situ nucleic acid hybridization of cytokines in primary biliary cirrhosis: predominance of the Th1 subset.

Authors:  K Harada; J Van de Water; P S Leung; R L Coppel; A Ansari; Y Nakanuma; M E Gershwin
Journal:  Hepatology       Date:  1997-04       Impact factor: 17.425

6.  Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice.

Authors:  Sabine Oertelt; Zhe-Xiong Lian; Chun-Mei Cheng; Ya-Hui Chuang; Kerstien A Padgett; Xiao-Song He; William M Ridgway; Aftab A Ansari; Ross L Coppel; Ming O Li; Richard A Flavell; Mitchell Kronenberg; Ian R Mackay; M Eric Gershwin
Journal:  J Immunol       Date:  2006-08-01       Impact factor: 5.422

7.  Elevations in IFN-gamma, IL-5, and IL-10 in patients with the autoimmune disease primary biliary cirrhosis: association with autoantibodies and soluble CD30.

Authors:  S M Krams; S Cao; M Hayashi; J C Villanueva; O M Martinez
Journal:  Clin Immunol Immunopathol       Date:  1996-09

8.  Natural killer T cells exacerbate liver injury in a transforming growth factor beta receptor II dominant-negative mouse model of primary biliary cirrhosis.

Authors:  Ya-Hui Chuang; Zhe-Xiong Lian; Guo-Xiang Yang; Shang-An Shu; Yuki Moritoki; William M Ridgway; Aftab A Ansari; Mitchell Kronenberg; Richard A Flavell; Bin Gao; M Eric Gershwin
Journal:  Hepatology       Date:  2008-02       Impact factor: 17.425

Review 9.  The causes of primary biliary cirrhosis: Convenient and inconvenient truths.

Authors:  M Eric Gershwin; Ian R Mackay
Journal:  Hepatology       Date:  2008-02       Impact factor: 17.425

10.  NOD.c3c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis.

Authors:  Junichiro Irie; Yuehong Wu; Linda S Wicker; Daniel Rainbow; Michael A Nalesnik; Raphael Hirsch; Laurence B Peterson; Patrick S C Leung; Chunmei Cheng; Ian R Mackay; M Eric Gershwin; William M Ridgway
Journal:  J Exp Med       Date:  2006-04-24       Impact factor: 14.307

View more
  17 in total

1.  Galectin-3 regulates inflammasome activation in cholestatic liver injury.

Authors:  Jijing Tian; Guoxiang Yang; Huan-Yuan Chen; Daniel K Hsu; Alexey Tomilov; Kristin A Olson; Ali Dehnad; Sarah R Fish; Gino Cortopassi; Bin Zhao; Fu-Tong Liu; M Eric Gershwin; Natalie J Török; Joy X Jiang
Journal:  FASEB J       Date:  2016-09-14       Impact factor: 5.191

Review 2.  Novel therapeutic targets in primary biliary cirrhosis.

Authors:  Jessica K Dyson; Gideon M Hirschfield; David H Adams; Ulrich Beuers; Derek A Mann; Keith D Lindor; David E J Jones
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-02-03       Impact factor: 46.802

Review 3.  Xenobiotics and loss of tolerance in primary biliary cholangitis.

Authors:  Jinjun Wang; Guoxiang Yang; Alana Mari Dubrovsky; Jinjung Choi; Patrick S C Leung
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

4.  Unmet challenges in immune-mediated hepatobiliary diseases.

Authors:  Ulrich Beuers; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

Review 5.  The coexistence of Sjögren's syndrome and primary biliary cirrhosis: a comprehensive review.

Authors:  Ying Sun; Weici Zhang; Baosen Li; Zhengsheng Zou; Carlo Selmi; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

6.  Successful immunotherapy of autoimmune cholangitis by adoptive transfer of forkhead box protein 3(+) regulatory T cells.

Authors:  H Tanaka; W Zhang; G-X Yang; Y Ando; T Tomiyama; K Tsuneyama; P Leung; R L Coppel; A A Ansari; Z X Lian; W M Ridgway; T Joh; M E Gershwin
Journal:  Clin Exp Immunol       Date:  2014-11       Impact factor: 4.330

7.  Chronic expression of interferon-gamma leads to murine autoimmune cholangitis with a female predominance.

Authors:  Heekyong R Bae; Patrick S C Leung; Koichi Tsuneyama; Julio C Valencia; Deborah L Hodge; Seohyun Kim; Tim Back; Megan Karwan; Anand S Merchant; Nobuyuki Baba; Dechun Feng; Ogyi Park; Bin Gao; Guo-Xiang Yang; M Eric Gershwin; Howard A Young
Journal:  Hepatology       Date:  2016-06-15       Impact factor: 17.425

Review 8.  Animal models of primary biliary cirrhosis.

Authors:  Tomohiro Katsumi; Kyoko Tomita; Patrick S C Leung; Guo-Xiang Yang; M Eric Gershwin; Yoshiyuki Ueno
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

Review 9.  A contemporary perspective on the molecular characteristics of mitochondrial autoantigens and diagnosis in primary biliary cholangitis.

Authors:  Patrick S C Leung; Jinjung Choi; Guoxiang Yang; Elena Woo; Thomas P Kenny; M Eric Gershwin
Journal:  Expert Rev Mol Diagn       Date:  2016-03-30       Impact factor: 5.225

10.  AAV-IL-22 modifies liver chemokine activity and ameliorates portal inflammation in murine autoimmune cholangitis.

Authors:  Yu-Hsin Hsueh; Yun-Ning Chang; Chia-En Loh; M Eric Gershwin; Ya-Hui Chuang
Journal:  J Autoimmun       Date:  2015-11-01       Impact factor: 7.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.